SEC Company Response from Fresh2 Group Ltd (FRES) (CIK 0001786511) — Jul 9, 2021
Fresh2 Group Ltd (FRES) (CIK 0001786511)
Date: July 9, 2021 · CIK: 0001786511 · Accession: 0001104659-21-090420
AI Filing Summary & Sentiment
File numbers found in text: 001-39137
Referenced dates: July 6, 2021
Letter
Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission AnPac Bio-Medical Science Co., Ltd. Form 20-F for Fiscal Year Ended December 31, 2020 Filed April 30, 2021 File No. 001-39137
Dear Li Xiao and Ibolya Ignat:
AnPac Bio-Medical Science Co., Ltd., a company incorporated under the laws of the Cayman Islands (the “Company”), hereby responds to the comment letter from the staff (the “Staff”) of the Securities and Exchange Commission, dated July 6, 2021, regarding the Company’s annual report on Form 20-F for the year ended December 31, 2020 that was filed on April 30, 2021 (the “2020 Form 20-F”).
In accordance with the Staff’s comments, the Company has filed, as of the date hereof, the Amendment No.1 to its 2020 Form 20-F, which includes the updated certifications by its principal executive officer and principal financial officer as Exhibits 12.1 and 12.2, pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended.
Should you have any question regarding this response letter or the Amendment No. 1 to the Company’s 2020 Form 20-F, please contact Chris Chang Yu, the Chairman and Chief Executive Officer of the Company, by email at chris_yu@anpac.cn.
Very truly yours,
AnPac Bio-Medical Science Co., Ltd.
Show Raw Text
CORRESP
1
filename1.htm
July
9, 2021
Li Xiao
Ibolya Ignat
Division of Corporation Finance
Office of Life Sciences
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re:
AnPac Bio-Medical Science Co., Ltd.
Form 20-F for Fiscal Year Ended December 31, 2020
Filed April 30, 2021
File No. 001-39137
Dear Li Xiao and Ibolya Ignat:
AnPac Bio-Medical Science Co., Ltd., a company
incorporated under the laws of the Cayman Islands (the “Company”), hereby responds to the comment letter from the staff (the
“Staff”) of the Securities and Exchange Commission, dated July 6, 2021, regarding the Company’s annual report on Form
20-F for the year ended December 31, 2020 that was filed on April 30, 2021 (the “2020 Form 20-F”).
In accordance with the Staff’s comments,
the Company has filed, as of the date hereof, the Amendment No.1 to its 2020 Form 20-F, which includes the updated certifications by its
principal executive officer and principal financial officer as Exhibits 12.1 and 12.2, pursuant to Rule 13a-14(a) of the Securities Exchange
Act of 1934, as amended.
Should you have any question regarding this response
letter or the Amendment No. 1 to the Company’s 2020 Form 20-F, please contact Chris Chang Yu, the Chairman and Chief Executive
Officer of the Company, by email at chris_yu@anpac.cn.
Very truly yours,
AnPac Bio-Medical Science Co., Ltd.
By:
/s/ Chris Chang Yu
Name: Chris Chang Yu
Title: Chairman and Chief Executive Officer